Why do we need biosimilars?
A decade of advances in multiple myeloma and unanswered questions
How to address the issue of access to new drugs in multiple myeloma
Paul Richardson et al.
The rising cost of drugs and how to address it
Biosimilars: Making biological agents availble worldwide
Won Seog Kim